Guangdong Hybribio Biotech reports H1 loss, approves cash management of idle funds

Guangdong Hybribio Biotech has announced the disclosure of its 2025 semi-annual report. The company held its 29th board meeting on August 25, 2025, which approved several key resolutions. Among these, the board agreed to use temporarily idle raised funds, up to RMB270 million, for safe, liquid, and principal-protected cash management products, with a maximum term of one year. This decision is valid for 12 months and allows for rollover use within the approved limit.

The semi-annual report details a 22.96% decrease in operating income, amounting to RMB314,993,117.77, and a net loss attributable to shareholders of RMB89,591,424.25, a 16.46% increase in loss compared to the previous year. This performance is attributed to industry policy adjustments and HPV-DNA detection product centralized procurement, leading to reduced factory prices and gross profit margins. Additionally, medical laboratory services experienced an 18.85% revenue decrease, totaling RMB91,574,454.17, leading to operational losses due to high fixed costs. Medical and health management services also incurred initial losses.

The board also approved the re-election of non-independent and independent directors for the sixth board, as well as a proposal to revise the company's articles of association and internal governance systems. These decisions are set to be reviewed at the first extraordinary general meeting in 2025. The company will not distribute cash dividends, bonus shares, or convert capital reserves into share capital for the first half of 2025.